-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
Healthcare AI Shakeout: Health Systems Plan to Cut AI Vendors Nearly in Half by 2028, Black Book Finds
-
Sparta Capital Ltd. Announces Resumption of Trading
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
CORRECTION FROM SOURCE: Nixxy Announces 1-for-20 Reverse Stock Split
-
Olenox Secures Texas Pipeline Operating Permit, Clearing Path for Initial 4 MW Power Deployment
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
French inventor of abortion pill calls Wyoming ban 'scandalous'
French scientist Etienne-Emile Baulieu, known as the father of the abortion pill, said it was "scandalous" and "a setback for women's freedom" that the US state of Wyoming has banned the drug.
Baulieu, who at the age of 96 is still working on treatments for depression and Alzheimer's, did not mince his words about the ban.
"It is a setback for women's freedom, particularly for those in the most precarious position who do not have the means to go to another state" to get an abortion, he told AFP in an interview.
Last week Wyoming became the first US state to outlaw the use of the abortion pill.
It was the latest point marked for conservative anti-abortion activists in the United States after the Supreme Court overturned the constitutional right to the procedure last year, leaving the policy to individual states.
Baulieu said he had dedicated a large part of his life to "increasing the freedom of women," and the ban was a step in the opposite direction.
Born in Strasbourg in 1926 to Jewish parents, Baulieu was raised by his feminist mother after his father, a doctor, died when he was a boy. At the age of 15, Baulieu joined the French resistance against Nazi occupation.
He went on to become a self-described "doctor who does science," specialising in the field of steroid hormones.
Invited to work in the United States, Baulieu was noticed in 1961 by Gregory Pincus, known as the father of the contraceptive pill, who convinced him to focus on sex hormones.
Back in France, Baulieu designed a way to block the effect of the hormone progesterone, which is essential for the egg to implant in the uterus after fertilisation.
"I wanted to make a contragestive," which stops gestation, he told AFP.
Partnering with the French Roussel-Uclaf laboratory, the oral drug RU-486, also known as mifepristone, was developed in 1982, providing a safe and inexpensive alternative to surgical abortion.
But there was a long battle for the drug to become authorised in the United States, where anti-abortion activists dubbed it the "death pill".
- 'Fanaticism and ignorance' -
In early March, French President Emmanuel Macron praised Baulieu's resilience when he presented the scientist with the Grand-Croix de la Legion d'Honneur, the top rank in France's honours system.
"You, a Jew and a resistance fighter, you were overwhelmed with the most atrocious insults and even compared to Nazi scientists," Macron said.
"But you held on, for the love of freedom and science."
Baulieu's wife Simone Harari Baulieu, a media producer in France, said "adversity slides off him like water off a duck's back".
She added that the recent "step backwards" in the United States was propelled by "fanaticism and ignorance".
Even at age 96, Baulieu heads into his office at the Kremlin-Bicetre University Hospital in the southern suburbs of Paris three times a week.
Stacks of photos, diplomas and binders contain "the work of a lifetime," the scientist said, adding that he still wants to "be useful".
His latest award is pinned to his blue suit, but Baulieu said he "never seriously hoped to receive such honours".
"It was a pleasure, but what interests me is improving people's health."
- 'Driving force' -
The team in his lab are continuing research he began years ago aiming to prevent the development of Alzheimer's disease, as well as treatment for severe depression, for which clinical trials begin in the coming months.
Baulieu said "there is no reason we cannot find treatments" for both illnesses, which have stubbornly evaded many previous attempts.
Julien Giustiniani, the team leader at the Baulieu Institute, which was created to finance research into dementia, said Baulieu was "always enthusiastic".
"He is a driving force for us," Giustiniani said.
Though Baulieu now uses a cane to walk, he exudes a tireless energy.
He partly credits using DHEA, a natural hormone produced by the adrenal gland, which Baulieu first described in the 1960s and has been touted as an anti-ageing supplement.
The causes that have dominated his life were "women, brain health and longevity," Baulieu said.
"I would be bored if I did not work anymore," he added.
G.P.Martin--AT